Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sBE Device in Recurrent Glioblastoma
NCT05410301Withdrawn
- Start
- Apr 2023
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Open-label trial in glioblastoma (GBM). Primary endpoints: sBE Compliance at 8 weeks and Adverse Events at 8 weeks. Planned start Apr 2023; status: withdrawn.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05410301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410301.